Table 1.
Results of selected early phase therapeutic vaccine trials in patients with metastatic solid cancers since 2004
| Vaccine type | Reference | Cancer type | Vaccine | Total patients | Patients responding |
|---|---|---|---|---|---|
| Peptide | 158 | Melanoma | NY-ESO-1 + CpG | 8 | 0 |
| 159 | Melanoma | Multi-epitope vaccine alone | 17 | 2 (PR) | |
| 160 | Melanoma | gp100 + IFA +/- GM-CSF | 28 | 0 | |
| 161 | Melanoma | NY-ESO-1 + IFA | 37 | 1 (PR) | |
| 162 | Kidney | Multi-epitope vaccine + IFA | 10 | 0 | |
| 163 | Kidney | CA9 multi-epitope vaccine + IFA | 23 | 3 (PR) | |
| 164 | Lung | Multi-epitope vaccine + IFA | 63 | 1 (CR)/1 (PR) | |
| 165 | Lung | Telomerase peptides + IFA | 22 | 0 | |
| 166 | Breast | Survivin peptide +/− IFA | 17 | 0 | |
| 167 | Brain | WT1 + IFA | 21 | 2 (PR) | |
| 168 | Esophagus | CHP-NY-ESO-1 and CHP-Her2 peptides + OK-432 | 8 | 0 | |
| 169 | Esophagus | Multi-epitope vaccine + IFA | 10 | 1 (CR) | |
| 170 | Urothelial | Survivin peptide + IFA | 9 | 0 | |
| 171 | Gynecologic | WT1 peptide + IFA | 12 | 0 | |
| 172 | Multiple | Chimeric Her2 peptide + ISA 720 | 24 | 1 (PR) | |
| 173 | Multiple | CHP-Her2 +/− GM-CSF or OK-432 | 9 | 0 | |
| 174 | Multiple | WT1 + IFA | 10 | 1 (PR) | |
| 175 | Multiple | Telomerase peptides + IFA | 19 | 0 | |
| Response rate: | 13/347 (3.7%) | ||||
| Dendritic cell | 176 | Melanoma | Transduced with MART-1 | 17 | 0 |
| 177 | Melanoma | Pulsed with allogeneic tumor lysate | 7 | 0 | |
| 178 | Melanoma | Pulsed with allogeneic tumor lysate | 20 | 1 (CR)/1 (PR) | |
| 179 | Melanoma | Pulsed with autologous tumor lysate | 46 | 3 (CR)/3 (PR) | |
| 180 | Melanoma | Transfected with RNA | 20 | 0 | |
| 181 | Melanoma | Pulsed with peptides | 12 | 0 | |
| 182 | Kidney | Pulsed with peptides | 30 | 0 | |
| 183 | Kidney | Allogeneic DC fused with autologous tumor | 20 | 2 (PR) | |
| 184 | Breast | Pulsed with peptides | 26 | 0 | |
| 185 | Thyroid | Pulsed with allogeneic tumor lysate | 10 | 0 | |
| 186 | Multiple | Pulsed with CEA peptide | 9 | 0 | |
| 187 | Multiple | Pulsed with mannan-MUC1 fusion protein | 10 | 0 | |
| 188 | Multiple | Modified with pox-virus encoding CEA + TRICOM | 13 | 0 | |
| Response rate: | 10/240 (4.2%) | ||||
| Virus | 189 | Melanoma | Heterologous prime-boost poxvirus-tyrosinase | 13 | 0 |
| 190 | Kidney | Poxvirus-encoded 5T4 | 13 | 0 | |
| 191 | Prostate | Heterologous prime-boost poxvirus-PSA + TRICOM | 7 | 0 | |
| 192 | Colorectal | Poxvirus-encoded 5T4 | 17 | 0 | |
| 193 | Multiple | Poxvirus-encoded CEA + TRICOM | 58 | 1 | |
| Response rate: | 1/108 (0.9%) | ||||
| Protein | 194 | Melanoma | NY-ESO-1 protein + ISCOMATRIX | 27 | 0 |
| PBMC | 195 | Lung | αGalCer-pulsed PBMC cultured with IL-2 + GM-CSF | 17 | 0 |
| Ganglioside | 196 | Melanoma | Ganglioside + IFA | 22 | 1 (PR) |
| Endothelial cell | 197 | Multiple | Fixed human umbilical vein endothelial cells | 9 | 1 (CR)/2 (PR) |
| RNA | 198 | Melanoma | Autologous tumor mRNA | 8 | 0 |
| Response rate: | 4/83 (4.8%) | ||||
| Tumor cells | 199 | Lung | Allogeneic tumor line transduced with antisense TGF-β2 | 21 | 0 |
| 200 | Lung | Autologous tumor mixed with allogeneic GM-CSF transduced tumor | 49 | 0 | |
| 201 | Mesothelioma | Autologous tumor + GM-CSF | 22 | 0 | |
| 202 | Brain | Autologous tumor transduced with antisense TGF-β2 | 6 | 2 (PR) | |
| Response rate: | 2/98 (2.0%) | ||||
| Plasmid DNA | 203 | Melanoma | MART-1 and Tyrosinase | 19 | 0 |
| 204 | Melanoma | gp100 +/− GM-CSF | 8 | 0 | |
| 205 | Head and neck | Hsp65 | 21 | 4 (PR) | |
| 206 | Multiple | NY-ESO-1 | 3 | 0 | |
| Response rate: | 4/51 (7.8%) | ||||
| Overall response rate: | 34/927 (3.7%) |
*
Some trials contain fewer reported total numbers of patients than in the primary report as only patients with evaluable disease at the time of enrollment are included on this table.